...
首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-gamma autoantibodies in patients with disseminated nontuberculous mycobacterial infection
【24h】

Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-gamma autoantibodies in patients with disseminated nontuberculous mycobacterial infection

机译:在筛选患者中与脱褐色的分枝杆菌感染患者中和抗干扰素-γ自身抗体的筛选中的使用在筛选中使用量子 - TB金管测定

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Anti-interferon-gamma (IFN-gamma) autoantibodies (anti-IFN-gamma Abs) have been increasingly recognized as an important cause of disseminated nontuberculous mycobacterial (DNTM) infection, and identification of this immunodeficiency impacts clinical management. However, the protean disease manifestations and inaccessibility to diagnostic tests in clinical settings hamper its early diagnosis. Here, we sought to determine whether QuantiFERON-TB Gold In-tube (QFT-GIT), a commercialized IFN-gamma release assay, could be used to screen for neutralizing anti-IFN-gamma Abs among previously healthy adults with DNTM infection.
机译:目的:抗干扰素 - γ(IFN-Gamma)自身抗体(抗IFN-Gamma ABS)越来越被认为是弥散不染色的分枝杆菌(DNTM)感染的重要原因,并鉴定这种免疫缺陷影响临床管理。 然而,临床环境中的蛋白疾病表现和诊断试验的可动性阻碍了其早期诊断。 在这里,我们试图确定Quantiferon-Tb金中管(QFT-git),商业化的IFN-Gamma释放测定,可用于筛选以预先健康的成年人中和抗IFN-Gamma ABS,DNTM感染。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号